Open 7 Days, 8 AM10 PM | Las Vegas Los Angeles Miami Fort Lauderdale Orange County Medical Disclaimer Medical Disclaimer: The information on this page is for educational purposes only and is not intended as medical advice
Firstly, you might experience fatigue as a side effect of semaglutide
Indeed, CDER Acting Director Michael Davis reinforced the policy point publicly on X, emphasizing that compounded GLP1 products are not FDAapproved and have not undergone the rigorous review for safety, efficacy, and manufacturing quality that is required for drugs approved through the new drug application (NDA) or abbreviated new drug application (ANDA) pathways.[3] This is now the third major set of warning letters in less than a year with the majority aimed at telehealth marketing of compounded GLP-1 products: September 2025: roughly 80 warning letters and 40 untitled letters March 2026: 30 warning letters June 2026: 25 warning letters The Claims FDA Is Targeting As in earlier rounds, the June 2026 letters appear highly standardized and focus on consumerfacing promotion of compounded GLP-1 products
.jpg?auto=format%2Ccompress&fmt=webp&width=720)
Type 1 Diabetes and Severe Kidney Disease Semaglutide was designed primarily for type 2 diabetes and weight lossnot type 1 diabetes, where it poses unique risks of diabetic ketoacidosis (DKA)
GLP-1 drug liraglutide may protect against dementia